Ursodeoxycholic Acid (UDCA) in Biliary Diseases: A Clinical Review

Massimo Milani1*

1Solo Practice, Via A. Nota 18, 20126 Milan, Italy.

Author's contribution

Author MM wrote the article and approved the final version.

Received 27th September 2013
Accepted 29th November 2013
Published 9th January 2014

ABSTRACT

Ursodeoxycholic acid (UDCA) is an established and accepted treatment of biliary diseases such as gallstones and primary biliary cirrhosis. Mechanisms of action of UDCA are not so far completely elucidated. UDCA tablets are indicated for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder and in the treatment of primary biliary cirrhosis (PBC). The Food and Drug Administration's Gastrointestinal Drugs Advisory Committee has stated that UDCA is safe and effective for the treatment of primary biliary cirrhosis. More recent Meta-analysis have cast doubt on the real impact of UDCA in patients with PBC. However more recent articles and systematic reviews have pointed out that the risk of death or liver transplantation was reduced by 32% in PBC patients treated with UDCA compared to placebo. In this review we summarized the principal evidence of efficacy of UDCA in the treatment of biliary diseases. UDCA remains so far a relevant pharmacological treatment in biliary diseases.

Keywords: Ursodeoxycholic; biliary diseases; review.

1. INTRODUCTION

Ursodeoxycholic acid (UDCA; 3, 7-dihydroxy-5-cholanic acid) (Fig. 1.) is a hydrophilic bile acid that is increasingly used for the treatment of various cholestatic disorders [1]. It is normally present in human bile, albeit in a low concentration of only about 3% of total bile
acids [2]. UDCA is used in several biliary diseases [3] from bile duct stone to the treatment of cholestasis in parenteral nutrition patients and in the treatment of primary biliary cirrhosis [4]. UDCA is also used in the prophylaxis of gallstones during rapid weight reduction [5]. A Cochrane review [6] has been quite recently published in order to evaluate if UDCA has any beneficial effect in primary biliary cirrhosis patients included 16 randomized clinical trials with a total of 1447 patients. The primary outcome measures were mortality and mortality or liver transplantation. Although treatment with UDCA showed a reduction in liver biochemistry, jaundice, and ascites, it did not decrease mortality or liver transplantation. More recent articles and systematic reviews have pointed out in PBC UDCA treatment significantly reduces the risk of death or liver transplantation in comparison with placebo. UDCA is the only FDA-approved medical treatment for PBC and should be administered at a recommended dose of 13-15mg/kg/day [7]. Up to 66% of patients with PBC respond to this treatment [8]. UDCA tablets are mainly indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gallstones in patients with a functioning gall bladder.

2. PHARMACOLOGY OF UDCA

Ursodeoxycholic acid (UDCA) is a derivative of chenodeoxycholic acid [9]. Conversion of chenodeoxycholic acid into ursodeoxycholic acid occurs in two stages via 7- ketolithocholic acid. UDCA acid is a secondary bile acid (produced in the gut) as well as a tertiary bile acid (produced in the liver) [10]. Oral bioavailability of UDCA is quite good: about 30-60% of orally administered UDCA is absorbed [11]. Although poorly water soluble in the protonated form, unconjugated UDCA acid is absorbed along the entire length of the jejunum and ileum by non-ionic passive diffusion; about 20% may be absorbed in the colon. The absorption of free UDCA is facilitated by prior solubilisation by other bile acids. Hence, it is advisable that UDCA acid should be taken with a meal that induces gallbladder contraction [12]. The absorption of UDCA can also be enhanced by administering it as a water-soluble taurine conjugate. Binding agents such as antacids, charcoal and cholestyramine impair the absorption of UDCA. The high first-pass metabolism (70%) results in low blood levels of UDCA after an oral dose. The half-life of UDCA is 3.6 to 5.8 days in humans [13]. UDCA may act by several mechanisms, all of which are poorly understood [14]. The most obvious one is a relative decrease in the toxic hydrophobic bile acids. The major mechanism by which UDCA achieve bile desaturation is through a decrease in secretion of cholesterol into the bile [15]. UDCA reduces cholesterol absorption, suppresses liver cholesterol synthesis and does not inhibit bile acid synthesis [16]. UDCA is able to alter bile composition from supersaturated to unsaturated [17]. Ursodiol also promotes the formation of liquid cholesterol crystal complexes which enhance removal of the cholesterol from the gallbladder into the intestine to be expelled. It has been suggested that the hydrophilic nature of UDCA confers cytoprotection in necro-inflammatory diseases of the liver [18]. Although the mechanism by which this is achieved is far from understood, some recent data support its effects, both on the cell membrane and the cellular signal transduction.
3. UDCA IN GALL STONES

Cholesterol gallstone disease is a common clinical condition influenced by genetic factors, increasing age, female gender and metabolic factors [19]. Laparoscopic cholecystectomy is currently considered the gold standard in treating patients with symptomatic gallstones [20]. Drugs with cholesterol-lowering properties which inhibit cholesterol synthesis or intestinal cholesterol absorption or drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis, might be proposed as additional approaches for treating cholesterol gallstones [21]. UDCA is indicated in chemodissolution of bile duct stone [21]. UDCA is more hydrophilic and less toxic than CDCA and is currently employed for oral litholysis of small cholesterol gallstones in patients with a functioning gallbladder [22]. This bile acid, in a dose of 10-14 mg/kg per day, increases its proportion in the bile acid pool (it originally accounts for less than 8%-10% of the biliary bile acid pool in healthy subjects), inducing a decreased hepatic secretion of biliary cholesterol and the formation of unsaturated gallbladder bile. The fine mechanisms involved in UDCA-induced dissolution of cholesterol stones are rather complex [23]. The so-called ternary phase diagram is used to explain the molecular effects of UDCA on bile composition and cholesterol solubility. A bedtime administration of UDCA or TUDCA, is recommended since it maintains hepatic bile acid secretion rate overnight, thus reducing secretion of supersaturated bile and increasing the dissolution rate [21]. The hydrophilic bile acid UDCA is also able to act as alitholytic agent through the reduction of intestinal cholesterol absorption and as a possible “prokinetic” agent capable of ameliorating postprandial gallbladder emptying as suggested by observations in vitro on isolated gallbladder smooth muscle strips from both animals and gallstone patients [24]. The improvement of gallbladder smooth muscle contractility probably also results from the prevention of the impairment of smooth muscle contractility induced by the more hydrophobic and toxic deoxycholate [25]. UDCA therefore could be viewed as the medical treatment of choice for dissolution of cholesterol gallstones [26]. So far, there is no evidence that UDCA could replace or reduce the need for cholecystectomy. However, the drug should be considered an attractive alternative to surgery in selected patients and should be considered over chenodiol when drug therapy for gallstones is indicated. In this clinical indication the recommended oral dosage of UDCA for the treatment of radiolucent, non-calcified gallstones of less than 20 mm in diameter is 8 to 10 milligrams/kilogram/day in
British Journal of Medicine & Medical Research, 4(9): 1783-1790, 2014

2 to 3 divided doses [27]. In general clinical symptoms with gallstone disease are reduced after 3 months of UDCA treatment [28].

4. UDCA IN PRIMARY BILIARY CIRRHOSIS

Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts with cholestasis, portal inflammation and fibrosis which may lead to cirrhosis, to its complications, and eventually to liver transplantation or death [29]. This autoimmune illness has a familial predisposition, in which even unaffected family members may have immunologic abnormalities, especially an increased serum immunoglobulin M (IgM) and an association with human leucocyte antigen (HLA)-DR8 [30].

The diagnosis of PBC is currently based on three criteria [31]: the presence of AMA and AMA-M2 in serum which is highly specific for the disease, elevation of biochemical indices of cholestasis for more than 6 months, and histological features in the liver that are indicative of the diagnosis [32]. The rationale for the use of UDCA in the treatment of PBC depends on its capability in displacing and diluting hepatotoxic bile acids from the bile acid pool. It is well known that in cholestatic conditions, endogenous bile acids are retained within hepatocytes, thus leading to the progressive deterioration of liver function [33]. Also fibrates are used in this condition even if so far there are not conclusive data on this indication [34]. The only accepted treatment for PBC is UDCA [35] that actually may delay but not completely cure or halt the progression of the disease. Clinical studies have shown that the effective UDCA dose in this clinical setting is 13 to 15 milligrams/kilogram/day, in two to four divided doses [36]. UDCA is in fact considered the first-line therapy for PBC. The rationale for the use of UDCA in the treatment of PBC depends on its ability in displacing and diluting detergent and hepatotoxic bile acids from the bile acid pool [37]. It is well known that in cholestatic conditions, endogenous bile acids are retained within hepatocytes, thus leading to the progressive deterioration of liver function [38]. The beneficial effects of UDCA on indices of liver dysfunction have been attributed to its physicochemical properties, since UDCA is very hydrophilic and therefore non-toxic to biological membranes [39]. Immunomodulatory effects of UDCA have been also described [40].

A number of randomized controlled studies have been conducted to evaluate UDCA efficacy [41]. In all studies UDCA was well tolerated since no relevant side effects were reported. In all studies a significant improvement of serum liver enzymes markers of cholestasis and cytolysis occurred. Serum concentrations of bilirubin, the most important prognostic marker of the disease, were reduced by UDCA administration [42]. A consistent reduction of IgM, which is an immunological marker of PBC was also reported [43]. UDCA improves both serum liver biochemistries and histology of PBC patients [44]. UDCA administered over a range of 9 months to 2 years has been found to significantly improve liver function tests in patients with primary biliary cirrhosis [45]; UDCA does not act on the aetiology of the disease but reverses the detrimental effects of the retention of endogenous bile acids within the liver. However, some studies have shown no benefit in survival outcomes with UDCA therapy [46] and two meta-analyses [47,48] have demonstrated that actually there was no survival difference between UDCA-treated patients compared to place-treated patients [5,49]. In particular Triatos et al. [39] evaluating at total of 8 trials found that here was no significant difference in mortality, in pruritus, in fatigue, in cholangiocarcinoma and in histology stage progression in patients treated with UDCA in comparison with placebo. On the contrary a significant improvement of survival could be recorded only in patients with serum bilirubin higher than 1.4 mg/dL at baseline [50]. These two meta-analyses included studies of short duration and those that used an inadequate dose of UDCA. A more recent meta-analysis [51] addressed these concerns and found that the risk of death or liver transplantation was reduced by 32% in patients treated with UDCA compared to placebo [52]. A subsequent combined analysis of the three largest clinical trials
showed that UDCA prolongs survival free of liver transplantation [49]. Long-term treatment with UDCA appears to slow disease progression and has altered the natural history of PBC [53]. Boberg [54] in a prospective long term observational study carried out in 182 PBC patients treated with UDCA demonstrated that UDCA oral treatment is a dominant strategy conferring reduced morbidity and mortality, as well as cost savings, compared with standard therapy. These data therefore reinforce the clinical utility of UDCA in PBC treatment strategy [49] even if UDCA treatment probably could have a significant benefit in patients with early disease stages. The benefit could be limited in those with already cirrhosis or more advance disease. Recently Lens et al. [55] have shown that combination treatment of bezafibrate and UDCA is associated with marked decrease or normalization of alkaline phosphatase as early as 3 months in patients with PBC.

5. CONCLUSION

UDCA could be yet considered a first-line pharmacological treatment for biliary diseases. UDCA tablets are indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder. UDCA remains a relevant pharmacological treatment in biliary diseases.

CONSENT

Not applicable.

ETHICAL APPROVAL

Not applicable.

COMPETING INTERESTS

The author reports no conflict of interest.

REFERENCES

1. Tint GS, Salen G, Colalillo A, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med. 1982;97:351-356.
2. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid the mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001;35:134-146.
3. Castiella A, Iribarren JA, Lopez P. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy. Am J Med. 1997;103(2):170-1.
4. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology. 1998;28:1449-1453.
5. Guslandi M. Treatment of chronic liver disease with ursodeoxycholic acid. J Int Med Res. 1990;18(6):497-505.
6. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. CochraneDatabase of Systematic Reviews. 2012;12. Art. No.: CD000551. DOI: 10.1002/14651858.CD000551.pub3
7. Anon: AxcanPharmaUrso for primary biliary cirrhosis approval recommended. FDC Reports: Prescription and OTC Pharmaceuticals. The Pink Sheet. 1996;58:T&G2.
8. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, Gatzen M, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989;97:1268-1274.
9. Ward A, Brogden RN, Heel RC, et al. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1984;27:95-131.
10. Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi Ursodeoxycholic acid in the Ursidae: biliary bile acids of related carnivores. J Lipid Res 1993;34:1911-1917.
11. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl. 1994;29(Suppl 204):1-15.
12. Product Information: URSO(R) oral tablets, ursodiol oral tablets. Axcan Scandipharm Inc, Birmingham, AL; 2008.
13. Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis (Part II). Dig Dis Sci 1982;27:833-856.
14. Maton PN, Murphy GM, Dowling RH. Ursodeoxycholic acid treatment of gallstones: dose response study and possible mechanism of action. Lancet 1977;2:1297-1301.
15. Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, Northfield TC. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994;106:134-142.
16. Salen G: Clinical perspective on the treatment of gallstones with ursodeoxycholic acid. J Clin Gastroenterol. 1988;10(suppl 2):S12-S17.
17. AMA Department of Drugs AMA Department of Drugs: Drug Evaluations Subscription, 6th. American Medical Association, Chicago, IL; 1986.
18. Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology. 1993;104:1736-1744.
19. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230-239.
20. Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am. 1991;20:1-19
21. Portincasa P, Di Ciaula A, Wang HH, Moschetta A, Wang DQ. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem. 2009;16:1531-1542.
22. Hofmann AF: Medical treatment of cholesterol gallstones by bile desaturating agents. Hepatology 1984;4(suppl 5):199S-208S.
23. Nakagawa S, Makino I, Ishizaki T, et al. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet. 1977;2:367-369.
24. Miyazaki K. Effects of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes. Dig Dis Sci. 1984;29:1123-30.
25. Portincasa P. Gallbladder and bile in health and gallstone disease: The role of motility, gallstones and bile lipid composition. Utrecht: PhD Thesis Utrecht University; 1995.
26. Anonymus: Tokyo Cooperative Gallstone Study Group: Efficacy and indications of ursodeoxycholic acid treatment for dissolving gallstones. Gastroenterology. 1980;78:542-548.
27. Bateson MC, Ross PE, Murison J, et al. Comparison of fixed doses of chenodeoxycholic acid for gallstone dissolution. Lancet. 1978;1:1111-1114.
28. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol. 1994;29:27-31.
29. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New England Journal of Medicine. 2005;353:1261-1273.
30. Solis H, Solis M, Muñoz Y. The pathogenesis of primary biliary cirrhosis. SB - Rev Esp Enferm Dig. 2009;101(6):413-23TA.
31. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261-1273.
32. Hohenester S, Oude-Ellerink RP, Beuers U. Primary biliary cirrhosis. Seminars Immunopathology. 2009;31:283–307.
33. Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J. 1983;59(Suppl 4):106-115.
34. Honda A, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931-41. doi: 10.1002/hep.26018. Epub 2013 Apr 5.
35. Burroughs AK, Leandro G, Goulis J. Ursodeoxycholic acid for primary biliary cirrhosis. J Hepatol. 2001;34:352–353.
36. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884-890.
37. Douglas L, Nguyen MD, Brian D, Juran BS, Konstantinos N. Lazaridis, MD*Primary Biliary Cirrhosis. Best Pract Res Clin Gastroenterol. 2010;24(5):647–654.
38. Liberal R, Grant CR, Sakka L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013;19. doi:pii: S2210-7401(13)00092-2.
39. Product Information: ACTIGALL(R) oral capsule, ursodiol oral capsule. Watson Pharmaceutical, Inc., Corona, CA; 2007.
40. Miyaguchi S, Mori M. Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model. Hepatogastroenterology. 2005;52(62):596-602.
41. Rolandi E, Franceschinin R, Cataldi A, et al. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. Eur J Clin Pharmacol. 1991;40:473-476.
42. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. Journal of Hepatology. 2000;32:561–566.
43. Buzzelli G, Moscarella S, Focardi G, et al. Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis. CurrTher Res. 1991;50:635-642.
44. Heathcote EJ, Cauch-Dudek K, Walker V, et al. "The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis," Hepatology. 1994;19(5):1149–1156.
45. Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22(3):759–766.
46. Eriksson S, Olsson R, Glauamn H, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scandinavian Journal of Gastroenterology. 1997;32(2):179–186.
47. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354(9184):1053–60.
48. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev; 2002. (1) CD000551.
49. Triantos CK, Koukias NM, Nikolopoulos VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34(8):901-10.
50. Parés, Albert, Llorenç Caballería and Juan Rodés. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterol. 2006;130(3):715-720.

51. Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol. 2008;14(21):3313-27.

52. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. Journal of hepatology. 2000;32(1 Suppl):129–40.

53. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol. 2007;41(5):494–500. [PubMed:17450033]

54. Boberg KM, Wisloff T, Kjøllesdal KS, Støvring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment PharmacolTher. 2013;36(7):794-803. doi:10.1111/apt.12435. E pub. 2013;5. PubMed PMID: 23915021.

55. Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2013;31. doi: 10.1111/liv.12290. [Epub aheadof print]

© 2014 Milani; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history.php?id=395&id=12&aid=3140